logo-loader

Arecor licenses first formulation to partner Inhibrx, taking their lung disease product to clinic

Published: 14:52 17 Dec 2020 GMT

Arecor Ltd's CEO Sarah Howell caught up with Proactive London's Katie Pilbeam about their peer review paper on their first clinical trial of proprietary product, AT247, which has been published in the prestigious medical journal Diabetes Care.

In terms of news flow, their first patient has been dosed in a phase 1 clinical trial for their second product, AT278, a new ultra-concentrated rapid insulin.

And their partner INHIBRX has licensed an option to take their liquid formulation of their product to the clinic.

Arecor Therapeutics announces collaboration on oral GLP-1 drug for diabetes...

Arecor Therapeutics PLC (AIM:AREC) CEO Sarah Howell joined Proactive's Stephen Gunnion with details of a collaboration with TRX Biosciences to develop an oral GLP-1 product for treating type 2 diabetes and obesity. GLP-1s are therapeutic peptides known for improving blood sugar levels and...

2 weeks, 1 day ago